Jarrett Jennifer 4

What Happened

• Jennifer Jarrett, COO of Arcus Biosciences, was granted a total of 157,000 equity units on January 23, 2026: 31,000 shares reported as acquired and 126,000 derivative shares (restricted stock units). Both items were reported at $0 purchase price (typical for equity awards), totaling 157,000 issued/awarded shares.

Key Details

• Transaction date: 2026-01-23; filing date: 2026-01-26 (filed within standard reporting window).
• Reported amounts: 31,000 shares acquired (direct) and 126,000 RSUs (derivative) — price $0.00 for each line.
• Vesting/terms: Footnote indicates the RSU grant vests in four equal annual installments beginning December 15, 2026 (F1). F2 notes that shown holdings include unvested RSU portions. F3 references an option schedule (48 monthly installments after Jan 1, 2026) included in the filing notes.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Transaction type code: A = Award/Grant (not a purchase or sale).

Context

• These are equity compensation awards (RSUs and shares) rather than open-market purchases or sales. RSUs are a derivative award that convert to company stock only as they vest; they do not indicate an immediate buy/sell signal. The filing was timely, so there’s no late-report implication.